WO2011061519A3 - Composition de mousse topique - Google Patents

Composition de mousse topique Download PDF

Info

Publication number
WO2011061519A3
WO2011061519A3 PCT/GB2010/002164 GB2010002164W WO2011061519A3 WO 2011061519 A3 WO2011061519 A3 WO 2011061519A3 GB 2010002164 W GB2010002164 W GB 2010002164W WO 2011061519 A3 WO2011061519 A3 WO 2011061519A3
Authority
WO
WIPO (PCT)
Prior art keywords
foam composition
topical foam
composition
topical
rifaximin
Prior art date
Application number
PCT/GB2010/002164
Other languages
English (en)
Other versions
WO2011061519A2 (fr
Inventor
Amar Lulla
Geena Malhotra
Original Assignee
Cipla Limited
Curtis, Philip, Anthony
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR112012012316A priority Critical patent/BR112012012316A2/pt
Application filed by Cipla Limited, Curtis, Philip, Anthony filed Critical Cipla Limited
Priority to NZ600362A priority patent/NZ600362A/en
Priority to JP2012540490A priority patent/JP2013511570A/ja
Priority to RU2012126084/15A priority patent/RU2012126084A/ru
Priority to CN2010800581391A priority patent/CN102724960A/zh
Priority to EP10784333.6A priority patent/EP2503989A2/fr
Priority to AU2010320656A priority patent/AU2010320656B2/en
Priority to CA2781580A priority patent/CA2781580A1/fr
Priority to MX2012005883A priority patent/MX2012005883A/es
Publication of WO2011061519A2 publication Critical patent/WO2011061519A2/fr
Publication of WO2011061519A3 publication Critical patent/WO2011061519A3/fr
Priority to US13/959,193 priority patent/US20130315998A1/en
Priority to US14/668,455 priority patent/US20150196488A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition pharmaceutique de mousse topique pour administration rectale, contenant de la rifaximine. L'invention concerne également un procédé de fabrication de la composition ainsi que l'utilisation de la composition comme médicament.
PCT/GB2010/002164 2009-11-23 2010-11-23 Composition de mousse topique WO2011061519A2 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
EP10784333.6A EP2503989A2 (fr) 2009-11-23 2010-11-23 Composition de mousse topique
NZ600362A NZ600362A (en) 2009-11-23 2010-11-23 Topical foam composition
JP2012540490A JP2013511570A (ja) 2009-11-23 2010-11-23 局所用泡沫組成物
RU2012126084/15A RU2012126084A (ru) 2009-11-23 2010-11-23 Пенная композиция для местного применения
CN2010800581391A CN102724960A (zh) 2009-11-23 2010-11-23 局部泡沫组合物
BR112012012316A BR112012012316A2 (pt) 2009-11-23 2010-11-23 composição farmacêutica para administração retal tópica na forma de espuma, uso de uma composição farmacêutica, método para tratamento, prevenção ou alívio de um dustúrbio no reto, cólon, íleo terminal ou ânus, processo para fabricação de uma composição farmacêutica contendo rifaximina, uso de um silicone e dispensador para composição farmacêutica
AU2010320656A AU2010320656B2 (en) 2009-11-23 2010-11-23 Topical foam composition
CA2781580A CA2781580A1 (fr) 2009-11-23 2010-11-23 Composition de mousse topique
MX2012005883A MX2012005883A (es) 2009-11-23 2010-11-23 Composicion topica en espuma.
US13/959,193 US20130315998A1 (en) 2009-11-23 2013-08-05 Topical Foam Composition
US14/668,455 US20150196488A1 (en) 2009-11-23 2015-03-25 Topical Foam Composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2703/MUM/2009 2009-11-23
IN2703MU2009 2009-11-23

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13511301 A-371-Of-International 2010-11-23
US13/959,193 Continuation US20130315998A1 (en) 2009-11-23 2013-08-05 Topical Foam Composition

Publications (2)

Publication Number Publication Date
WO2011061519A2 WO2011061519A2 (fr) 2011-05-26
WO2011061519A3 true WO2011061519A3 (fr) 2011-10-06

Family

ID=43447946

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2010/002164 WO2011061519A2 (fr) 2009-11-23 2010-11-23 Composition de mousse topique

Country Status (12)

Country Link
EP (1) EP2503989A2 (fr)
JP (1) JP2013511570A (fr)
KR (1) KR20120117788A (fr)
CN (1) CN102724960A (fr)
AU (1) AU2010320656B2 (fr)
BR (1) BR112012012316A2 (fr)
CA (1) CA2781580A1 (fr)
MX (1) MX2012005883A (fr)
NZ (1) NZ600362A (fr)
RU (1) RU2012126084A (fr)
WO (1) WO2011061519A2 (fr)
ZA (1) ZA201204018B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2522895T3 (es) 2005-03-03 2014-11-19 Alfa Wassermann S.P.A. Nuevas formas polimorfas de rifaximina, procedimientos para su producción y uso de las mismas en preparados medicinales
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
ATE429255T1 (de) 2005-03-24 2009-05-15 Nolabs Ab Kosmetische behandlung mit stickoxid, vorrichtung zur durchführung dieser behandlung und herstellungsverfahren dafür
EP4249001A3 (fr) 2009-08-21 2023-11-29 Novan, Inc. Gels topiques
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
EP2729131B1 (fr) 2011-07-05 2020-04-15 Novan, Inc. Compositions topiques
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
US11077194B2 (en) 2012-03-14 2021-08-03 Novan, Inc. Nitric oxide releasing pharmaceutical compositions
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
US9855211B2 (en) 2013-02-28 2018-01-02 Novan, Inc. Topical compositions and methods of using the same
US11813284B2 (en) 2013-08-08 2023-11-14 Novan, Inc. Topical compositions and methods of using the same
US10206947B2 (en) 2013-08-08 2019-02-19 Novan, Inc. Topical compositions and methods of using the same
WO2015173697A1 (fr) 2014-05-12 2015-11-19 Alfa Wassermann S.P.A. Nouvelle forme cristalline solvatée de la rifaximine, production, compositions et utilisations associées
JP7090549B2 (ja) 2016-03-02 2022-06-24 ノヴァン，インコーポレイテッド 炎症のための治療用組成物およびその治療方法
CN109310630A (zh) 2016-04-13 2019-02-05 诺万公司 用于治疗感染的组合物、系统、试剂盒和方法
CA3046938A1 (fr) * 2016-12-16 2018-06-21 Ferring B.V. Formulations de mousse rectale
EP3758679A4 (fr) 2018-03-01 2021-12-15 Novan, Inc. Suppositoires libérant de l'oxyde nitrique et leurs procédés d'utilisation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140355A (en) * 1991-12-17 2000-10-31 Alfa Wassermann S.P.A. Pharmaceutical compositions containing rifaximin for treatment of vaginal infections
WO2007103448A2 (fr) * 2006-03-09 2007-09-13 Salix Pharmaceuticals, Inc. Preparation anti-dysfonctionnement rectal de rifaximine
US20080063607A1 (en) * 2003-08-04 2008-03-13 Foamix Ltd Oleaginous pharmaceutical and cosmetic foam
WO2009137672A1 (fr) * 2008-05-07 2009-11-12 Salix Pharmaceuticals, Ltd. Procédés de traitement de maladie intestinale par l’administration d’un nettoyant d’intestin et d’un antibiotique

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2907118A1 (de) 1979-02-20 1980-09-04 Schering Ag Neue prostacyclin-derivate und verfahren zu ihrer herstellung
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
GB8909559D0 (en) 1989-04-26 1989-06-14 Smith Kline French Lab Pharmaceutical compositions
FR2647344B1 (fr) 1989-05-25 1995-06-02 Physiopharm Sarl Mousse aerosol a usage rectal
US4946939A (en) 1989-05-30 1990-08-07 The Dow Chemical Company High purity polyether polyols
IT1243379B (it) 1990-07-27 1994-06-10 Giuliani Spa Composizione farmaceutica adatta alla somministrazione rettale di principi attivi che esplicano un'azione di medicazione a livello del colon prevalentemente di tipo topico
IT1264494B1 (it) 1993-03-23 1996-09-24 Alfa Wassermann Spa Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter
IT1290679B1 (it) 1997-02-14 1998-12-10 Alfa Wassermann Spa Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi.
US7820145B2 (en) * 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
ES2522895T3 (es) 2005-03-03 2014-11-19 Alfa Wassermann S.P.A. Nuevas formas polimorfas de rifaximina, procedimientos para su producción y uso de las mismas en preparados medicinales
CN101502510B (zh) * 2009-03-19 2011-11-09 山东京卫制药有限公司 一种用于治疗阴道炎症的药物组合物及其制备方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140355A (en) * 1991-12-17 2000-10-31 Alfa Wassermann S.P.A. Pharmaceutical compositions containing rifaximin for treatment of vaginal infections
US20080063607A1 (en) * 2003-08-04 2008-03-13 Foamix Ltd Oleaginous pharmaceutical and cosmetic foam
WO2007103448A2 (fr) * 2006-03-09 2007-09-13 Salix Pharmaceuticals, Inc. Preparation anti-dysfonctionnement rectal de rifaximine
WO2009137672A1 (fr) * 2008-05-07 2009-11-12 Salix Pharmaceuticals, Ltd. Procédés de traitement de maladie intestinale par l’administration d’un nettoyant d’intestin et d’un antibiotique

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Remington:The science and pratice of pharmacy", 1 January 2000, 20000101, XP002617989 *
MILO GIBALDI, MARY LEE, ARCHANA DESAI: "Gibaldi's drug delivery systems in pharmaceutical care", 2007, AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS, article 7: "Rectal, Vaginal and Urethral delivery", pages: 98 - 98, XP002617991 *
RONALD P. EVENS: "Drug and biological development: from molecule to product and beyond", 2007, SPRINGER, USA, ISBN: 9780387329789, article PAVLIV, L.;CAHILL, J.F.: "Formulation and Manufacturing", pages: 214 - 214, XP002617990 *

Also Published As

Publication number Publication date
ZA201204018B (en) 2012-12-27
EP2503989A2 (fr) 2012-10-03
NZ600362A (en) 2014-08-29
MX2012005883A (es) 2012-10-09
JP2013511570A (ja) 2013-04-04
AU2010320656B2 (en) 2015-07-30
RU2012126084A (ru) 2013-12-27
AU2010320656A1 (en) 2012-06-21
KR20120117788A (ko) 2012-10-24
CA2781580A1 (fr) 2011-05-26
CN102724960A (zh) 2012-10-10
BR112012012316A2 (pt) 2016-04-26
WO2011061519A2 (fr) 2011-05-26

Similar Documents

Publication Publication Date Title
WO2011061519A3 (fr) Composition de mousse topique
WO2011061516A3 (fr) Composition de mousse topique
WO2011093825A3 (fr) Formes posologiques effervescentes comprenant un antibiotique du groupe des céphalosporines
WO2009085990A3 (fr) Procédés de préparation de sitagliptine et sels pharmaceutiquement acceptables de celle-ci
WO2011131943A3 (fr) Compositions pharmaceutiques
WO2014045162A8 (fr) Composés d'hexahydropyrano[3,4-d][1,3]thiazine-2-amine alkyl-substitués
WO2012034079A3 (fr) Formes pharmaceutiques de type macrolides
WO2012019426A8 (fr) Dérivé de phtalazinone, son procédé de préparation et utilisation pharmaceutique
WO2012019430A8 (fr) Dérivé de phtalazinone, son procédé de préparation et utilisation pharmaceutique
WO2010092090A3 (fr) Nouveaux sels de la sitagliptine
WO2012065019A3 (fr) Inhibiteurs pyridopyrimidinone de p13k alpha
MX2011012739A (es) Derivados fluorados de aminotriazol.
MY172422A (en) Pyrazole compound and pharmaceutical use thereof
WO2011019326A3 (fr) Formulation pharmaceutique permettant d'augmenter la solubilité et la stabilité
WO2011079193A3 (fr) Préparation de la bendamustine et de ses sels
WO2011009938A3 (fr) Stambomycine et dérivés, leur production et leur utilisation comme médicaments
WO2012135615A3 (fr) Enopeptines, utilisations de celles-ci, et procédés de synthèse de celles-ci
MX2012012941A (es) Nuevas composiciones oftalmicas.
EP3677261B8 (fr) Administration d'inhibiteurs de la protéase sérine dans l'estomac
WO2010121675A3 (fr) Thiazolyl-benzimidazoles
WO2012074869A8 (fr) Benzoxazépines en tant qu'inhibiteurs de pi3k/mtor, et leurs procédés d'utilisation et de fabrication
WO2011064558A3 (fr) Composition pharmaceutique
IL218008A (en) Dexbinol or its salt for non-melanoma cancer suppression, its use in the preparation of non-melanoma cancer suppressant, and a pharmacological preparation containing the said
WO2011135581A8 (fr) Compositions pharmaceutiques de dronédarone
WO2010148314A3 (fr) Préparation d'ésoméprazole et de ses sels pharmaceutiquement acceptables

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080058139.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10784333

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: MX/A/2012/005883

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2781580

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012540490

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2010320656

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 4808/DELNP/2012

Country of ref document: IN

Ref document number: 2010784333

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2010320656

Country of ref document: AU

Date of ref document: 20101123

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20127016200

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012126084

Country of ref document: RU

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012012316

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012012316

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120523